Funded Biotechnology Startups in Minneapolis
In the 13 most recent Minneapolis-based biotechnology rounds, one disclosed amount stands far above the rest: Medtronic’s Post-IPO Debt on 2022-09-15 is $3…
In the 13 most recent Minneapolis-based biotechnology rounds, one disclosed amount stands far above the rest: Medtronic’s Post-IPO Debt on 2022-09-15 is $3.5B, dwarfing the next-largest disclosed round from ALT5 Sigma Corp on 2025-08-11 ($1.5B) and all other values (e.g., Adialante at $500K on 2026-06-16). Stage classification is also skewed: 5 of 13 entries show “Series Unknown” (Imricor Medical Systems on 2026-05-03 for $43M; Nuvaira on 2026-03-04 for $36M; ALT5 Sigma Corp on 2025-08-11 for $1.5B; Luminary Therapeutics on 2025-03-11 for $6M; DiaMedica on 2023-06-21 for $38M).
The date window is recent but uneven: the newest round is Adialante on 2026-06-16 ($500K), while the oldest row shown is Medtronic’s 2022-09-15 debt round ($3.5B), spanning roughly four years. Several clusters appear by time density—multiple large “Series Unknown” rounds land in 2023 (DiaMedica $38M on 2023-06-21; Neurotype Inc. is Seed at $330K on 2023-07-01), and two top-tier deals sit in 2025 (FOXO Technologies $2M on 2025-06-04; ALT5 Sigma Corp $1.5B on 2025-08-11).
Most recent rounds
13 shownRelated listings
Frequently asked
What’s the largest disclosed funding amount in this Minneapolis biotechnology list, and how does it compare to the rest of the disclosed rounds?
Medtronic’s Post-IPO Debt on 2022-09-15 is the outlier at $3.5B. The only other disclosed amount above $1B is ALT5 Sigma Corp on 2025-08-11 at $1.5B; everything else is well below that, including Imricor Medical Systems at $43M (2026-05-03) and Adialante at $500K (2026-06-16).
Do entries concentrate in a narrow time window, or are rounds spread evenly across the date range shown?
Rounds span from 2022-09-15 (Medtronic, $3.5B) through 2026-06-16 (Adialante, $500K), so the shown window is multi-year. There are noticeable mid-series clusters around 2025–2026 for active disclosed rounds (e.g., Imricor on 2026-05-03 for $43M; Nuvaira on 2026-03-04 for $36M; FOXO on 2025-06-04 for $2M; ALT5 Sigma on 2025-08-11 for $1.5B).
Which stage labels dominate the list, and how much of the activity is “Series Unknown”?
“Series Unknown” appears in 5 of the 13 rows, covering Imricor Medical Systems ($43M on 2026-05-03), Nuvaira ($36M on 2026-03-04), ALT5 Sigma Corp ($1.5B on 2025-08-11), Luminary Therapeutics ($6M on 2025-03-11), and DiaMedica ($38M on 2023-06-21). Other explicit labels include Pre-Seed (Adialante, $500K on 2026-06-16), Seed (Neurotype Inc., $330K on 2023-07-01), Series B (Vergent Bioscience, $22M on 2022-10-04), and Post-IPO Debt (Medtronic, $3.5B on 2022-09-15).
Are there meaningful outliers on the low end of disclosed amounts?
Yes. The smallest disclosed amount is Evia Bio’s $10K on 2022-12-06, which is orders of magnitude below most other entries, including the next-lowest disclosed value around the same period such as Neurotype Inc. at $330K (2023-07-01) and Adialante at $500K (2026-06-16).
Are the highest-value rounds clustered around a particular scale band, or do they vary widely within the list?
They vary widely. After Medtronic’s $3.5B (2022-09-15), the list drops to the next scale band at ALT5 Sigma Corp’s $1.5B (2025-08-11), then into tens of millions (e.g., Nuvaira $36M on 2026-03-04; DiaMedica $38M on 2023-06-21; Marker Therapeutics $25M on 2022-12-13) and down to hundreds of thousands for smaller disclosed rounds like Adialante $500K (2026-06-16) and Neurotype Inc. $330K (2023-07-01).
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.